Tag: CX 2026
“Absence of endorsement is not absence of evidence”: CX 2026 peripheral session raises sirolimus-versus-paclitaxel debate
Debate over sirolimus versus paclitaxel drug-coated balloons (DCBs) in the femoropopliteal segment i...
Abbott unveils “promising” Esprit BTK post-approval study data
Initial data from the Esprit BTK post-approval study, presented at the 2026 Charing Cross (CX) Sym...
